TNG908, a Clinical Candidate for PRMT5 Inhibition Exploiting Synthetic Lethality with MTAP

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2024; 20(07): 0759
DOI: 10.1055/s-0043-1774882

Innovative Drug Discovery and Development

Contributor(s):

Antonia F. Stepan (Roche)

,

Seong Heon Kim (Hyundai Pharm)

PRMT5 - TNG908 - synthetic lethality - MTAP - brain penetrant - glioblastoma - clinical candidate

Article published online:
14 June 2024

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany